NCT00839397已完成3 期
BRL29060A in Posttraumatic Stress Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 52
- 主要终点
- Change from baseline in the Clinician-Administered Posttraumatic Stress Disorder Scale One Week Symptom Status Version (CAPS-SX) total score
研究概览
简要总结
This was a 52-week, non-comparative, uncontrolled study of paroxetine in Japanese PTSD patients to obtain clinical experience regarding efficacy and safety. In this study, subjects received paroxetine 20mg-40mg once daily after an evening meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a primary diagnosis of PTSD according to DSM-IV criteria (Posttraumatic Stress Disorder: 309.81). In order to diagnose PTSD, the Clinician-Administered PTSD Scale-DX Current and Lifetime Diagnostic Version (CAPS-DX) will be used.
- •Disease to Be Treated:
- •Duration of illness of at least 3 months at Week -
- •Score >= 50 on Criteria B, C and D of CAPS-SX.
- •Age: >=18 - <65 years (at the time of acquisition of informed consent)
- •Sex: No restriction
- •Hospitalization Status: No restriction
- •Informed consent: Gives his/her informed consent. In case of a subject who is under the age of 20, his/her parent/guardian must also give his/her written informed consent.
排除标准
- •Exclusion Criteria at Week -1
- •Patients diagnosed with Axis I disorders (excluding PTSD) such as major depression, dysthymia, simple phobia, OCD, or panic disorder as a primary diagnosis according to DSM-IV criteria within 24 weeks prior to Week -
- •However, patients with depressive disorders are allowed to enroll in the study, if PTSD was present before the depressive disorders appeared and PTSD is the predominant disorder.
- •Patients presenting a current major depressive episode that preceded the diagnosis of PTSD. However, patients with depressive disorders are allowed to enroll in the study, if PTSD was present before the depressive disorders appeared and PTSD is the predominant disorder.
- •Patients receiving disability payments because of PTSD or any other psychiatric disorder.
- •Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders.
- •Patients taking St. Johns Wort.
- •Patients who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within 24 weeks prior to Week -
- •Patients who have attempted suicide within 24 weeks prior to Week -1 or who pose, in the investigator's judgement using the M.I.N.I. "C. Suicidality", a high suicidal risk.
- •Women who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study.
- •Patients who have taken MAO inhibitors within 1 week prior to Week -1 (or within 2 weeks prior to Week 0).
- •Patients who have had electroconvulsive therapy (ECT) within 12 weeks prior to Week -
- •Patients who have been treated with another investigational drug within 12 weeks prior to Week -
- •Patients with a history or complication of manic psychosis.
- •Patients with a history or complication of convulsive disorder (epilepsy, etc.).
- •Patients with a complication of glaucoma.
- •Patients with a known tendency for bleeding or those with predisposing conditions.
- •Patients with a history of hypersensitivity to paroxetine.
- •Patients with any serious organic disorder in the brain.
- •Patients with any serious physical symptom such as cardiac, hepatic, renal or hematopoietic dysfunction.
- •Patients with a history or complication of cancer or malignant tumor.
- •Others whom the investigator or sub-investigator considers ineligible for the study.
- •Exclusion Criterion at Week 0
- •Patients whose placebo run-in medication compliance is less than 80%.
研究组 & 干预措施
Paroxetine
Other
A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
干预措施: Paroxetine (Drug)
结局指标
主要结局
Change from baseline in the Clinician-Administered Posttraumatic Stress Disorder Scale One Week Symptom Status Version (CAPS-SX) total score
时间窗: 52 weeks
次要结局
- Proportion of responders based on the CGI Global Improvement(52 weeks)
- Change from baseline in the CAPS-SX re-experiencing cluster score(52 weeks)
- Change from baseline in the CAPS-SX avoidance/numbing cluster score(52 weeks)
- Change from baseline in the CAPS-SX hyperarousal cluster score(52 weeks)
- Change from baseline in the CGI Severity of Illness score(52 weeks)
- Adverse events (AEs), abnormal findings in each examination/test, and their details: Laboratory tests (hematology, clinical chemistry, electrolytes, urinalysis), Blood pressure, pulse rate, body weight(52 weeks)
研究者
相似试验
尚未招募
4 期
A Clinical Study On Post Covid Stress Disorder And Its Homoeopathic ManagementCTRI/2022/04/041620S VIKRAM
已完成
不适用
Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress DisorderPost Traumatic Stress DisorderNCT01492699Resilience Government Services, Inc.7
已完成
2 期
Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure TherapyStress Disorders, Post-TraumaticNCT00215163Duke University17
已完成
2 期
A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep DisturbancesPosttraumatic Stress Disorder (PTSD)Sleep Disturbances and InsomniaNCT06685965Reconnect Labs12
已完成
4 期
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance DependencePTSDNCT00330239Medical University of South Carolina25